MA35029B1 - Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir - Google Patents

Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir

Info

Publication number
MA35029B1
MA35029B1 MA36310A MA36310A MA35029B1 MA 35029 B1 MA35029 B1 MA 35029B1 MA 36310 A MA36310 A MA 36310A MA 36310 A MA36310 A MA 36310A MA 35029 B1 MA35029 B1 MA 35029B1
Authority
MA
Morocco
Prior art keywords
hepatitis
treatment
alisporivir
virus infection
virus
Prior art date
Application number
MA36310A
Other languages
English (en)
Inventor
Claudio Avila
Rafael Crabbé
Original Assignee
Novartis Ag
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35029(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Int Sa filed Critical Novartis Ag
Publication of MA35029B1 publication Critical patent/MA35029B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'inhibiteurs de cyclophiline dans le traitement d'une infection par le virus de l'hépatite C.
MA36310A 2011-04-13 2012-04-11 Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir MA35029B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474946P 2011-04-13 2011-04-13
PCT/EP2012/056577 WO2012140082A1 (fr) 2011-04-13 2012-04-11 Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir

Publications (1)

Publication Number Publication Date
MA35029B1 true MA35029B1 (fr) 2014-04-03

Family

ID=45937376

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36310A MA35029B1 (fr) 2011-04-13 2012-04-11 Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir

Country Status (19)

Country Link
US (2) US20150104415A1 (fr)
EP (1) EP2696883A1 (fr)
JP (1) JP2014510772A (fr)
KR (1) KR20140011379A (fr)
CN (1) CN103648516A (fr)
AR (1) AR085988A1 (fr)
AU (2) AU2012241859A1 (fr)
BR (1) BR112013025934A2 (fr)
CA (1) CA2832829A1 (fr)
CL (1) CL2013002914A1 (fr)
IL (1) IL228725A0 (fr)
MA (1) MA35029B1 (fr)
MX (1) MX2013011941A (fr)
PH (1) PH12013502047A1 (fr)
RU (1) RU2013150344A (fr)
SG (2) SG10201602184TA (fr)
TN (1) TN2013000397A1 (fr)
TW (1) TW201247217A (fr)
WO (1) WO2012140082A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
WO2008052722A2 (fr) 2006-11-02 2008-05-08 Heidelberg Pharma Ag Utilisation de conjugués de ribavirine comme médicament anti-viral

Also Published As

Publication number Publication date
AU2012241859A1 (en) 2013-10-10
MX2013011941A (es) 2014-05-28
KR20140011379A (ko) 2014-01-28
CA2832829A1 (fr) 2012-10-18
SG193908A1 (en) 2013-11-29
JP2014510772A (ja) 2014-05-01
CL2013002914A1 (es) 2014-06-27
NZ615539A (en) 2016-01-29
IL228725A0 (en) 2013-12-31
TN2013000397A1 (en) 2015-01-20
US20160235808A1 (en) 2016-08-18
CN103648516A (zh) 2014-03-19
AR085988A1 (es) 2013-11-13
SG10201602184TA (en) 2016-04-28
WO2012140082A1 (fr) 2012-10-18
TW201247217A (en) 2012-12-01
PH12013502047A1 (en) 2019-03-22
US20150104415A1 (en) 2015-04-16
AU2016200061A1 (en) 2016-01-28
EP2696883A1 (fr) 2014-02-19
BR112013025934A2 (pt) 2016-09-06
RU2013150344A (ru) 2015-05-20

Similar Documents

Publication Publication Date Title
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
EP2680859A4 (fr) Compositions, méthodes de traitement et diagnostics dans le traitement de la stéatose hépatique seule ou en association avec une infection par le virus de l'hépatite c
EA201691837A1 (ru) Противовирусные агенты против гепатита в
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
PH12014502603A1 (en) D-amino acid compounds for liver disease
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
EA201592081A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРО-РНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-122
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EP2633865A4 (fr) Utilisation d'interleukine 22 dans le traitement d'une hépatite virale
EP2875024A4 (fr) Dérivés de pyrimidinone amido-substituée pouvant être utilisés en vue du traitement de l'infection par le vih
EA201391399A1 (ru) Макроциклическое соединение и способы его получения
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
EA201270798A1 (ru) Соединения для лечения гепатита с
EP2348848A4 (fr) Traitement d'une infection par l'hépatite c avec des métalloporphyrines
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c